In June 2023, TAP made an equity investment in Rgenta Therapeutics to "Support development of RNA-targeting molecules for blood cancers."
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Rgenta has a proprietary platform to mine the massive genomics data to identify targetable RNA processing events and to design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs.
Rgenta is working closely with TAP to further develop RNA-targeting molecules by supporting preclinical studies with the goal of moving towards clinical development in hematological malignancies.
For more information about Rgenta, visit rgentatx.com.
Recent News
- June 12, 2025 - presented preclinical data from RGT-61159 supporting its application in the treatment of AML at EHA 2025
- April 25, 2025 - presented preclinical data on RGT-61159 demonstrating anti-tumor activity in AML models at AACR 2025
- December 9, 2024 - presented preclinical data demonstrating anti-tumor activity of RGT-61159 in multiple models of AML at ASH 2024
- December 4, 2024 - announced a multi-year, multi-target strategic research alliance with GSK to advance the discovery and development of novel RNA-targeted small molecule splice modulators for multiple disease areas including oncology
- July 10, 2024 - announced the IND clearance for RGT-61159, which is being developed for the potential treatment of adenoid cystic carcinoma (ACC), colorectal cancer (CRC) and other solid tumors as well as AML.
- January 30, 2024 - announced that it was selected as a new Therapy Acceleration Program® (TAP) portfolio company